Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors
Daniel C ChoDivision of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USAAbstract: Tyrosine kinase inhibitors with activity against vascular endothelial growth factor receptor 2 are now standard treatment for the majority of patients with advanced renal cell carcinoma. T...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-06-01
|
| Series: | OncoTargets and Therapy |
| Online Access: | http://www.dovepress.com/prognostic-biomarkers-for-patients-with-advanced-renal-cell-carcinoma--a13326 |